Can mechanical heart valves perform similarly to tissue valves? An in vitro study.

Aortic valves Bioprosthetic heart valves Cardiovascular engineering Heart valve In vitro analysis Mechanical heart valves Medical devices Prosthetic heart valves Tissue heart valves

Journal

Journal of biomechanics
ISSN: 1873-2380
Titre abrégé: J Biomech
Pays: United States
ID NLM: 0157375

Informations de publication

Date de publication:
08 Aug 2024
Historique:
received: 04 06 2024
revised: 06 08 2024
accepted: 08 08 2024
medline: 14 8 2024
pubmed: 14 8 2024
entrez: 14 8 2024
Statut: aheadofprint

Résumé

Current surgical aortic valve (AV) replacement options include bioprosthetic and mechanical heart valves (MHVs), each with inherent limitations. Bioprosthetic valves offer superior hemodynamics but suffer from durability issues, typically initiating deterioration within 7-8 years. MHVs, while durable, necessitate lifelong anticoagulation therapy, presenting risks such as severe bleeding and thromboembolic events. The need for anticoagulants is caused by non-physiological flow through the hinge area during the closed phase and large spikes of regional backflow velocity (RBV) during the closing phase that produces high shear events. This study introduces the iValve, a novel MHV designed to combine the hemodynamic benefits of bioprosthetic valves with the durability of MHVs without requiring anticoagulation. The iValve features eye-like leaflets, a saddle-shaped housing, and an optimized hinge design to enhance blood flow and minimize thrombotic risk. Fabricated using 6061-T6 aluminum and polyether ether ketone (PEEK), twelve iValve iterations were evaluated for their opening and closing dynamics. The reported top-performing prototypes demonstrated competitive performance against industry standards. The proposed iValve prototype exhibited a mean RBV of -4.34 m/s with no spikes in RBV, performing similarly to bioprosthetic valves and significantly outperforming existing MHVs. The iValve's optimized design showed a 7-10% reduction in closing time and a substantial decrease in RBV spikes, potentially reducing the need for anticoagulation therapy. This study highlights the iValve's potential to revolutionize prosthetic heart valve technology by offering a durable, hemodynamically superior solution that mitigates the drawbacks of current MHVs.

Identifiants

pubmed: 39141959
pii: S0021-9290(24)00348-8
doi: 10.1016/j.jbiomech.2024.112270
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112270

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Dylan Goode (D)

The Heart Valve Performance Laboratory, School of Engineering, Faculty of Applied Science, University of British Columbia, Kelowna, BC, Canada.

Lawrence Scotten (L)

Independent consultant, Victoria, BC, Canada.

Rolland Siegel (R)

Independent consultant, Portland, OR, USA.

Hadi Mohammadi (H)

The Heart Valve Performance Laboratory, School of Engineering, Faculty of Applied Science, University of British Columbia, Kelowna, BC, Canada. Electronic address: hadi.mohammadi@ubc.ca.

Classifications MeSH